You have read all your free articles, to continue reading subscribe to read the rest of this content.
Sprint Bioscience is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer, Already a…
Immunicum has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence. Merging the complementary allogeneic dendritic cell biology approaches of both cAlready a subscriber Login You have…
BioArctic announces that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. The European patent EP2539366 covers the monoclonal antibody candidate BAN0805 per se, intended for treatment of neAlready a subscriber Login You have read…
Swedish Olink has gone through a formal reorganization, and as of April 1, 2016 it is operating as two separate companies, each with its own distinct focus area. Olink Proteomics will continue to expand and develop the Proseek Multiplex product line for targeted human protein biomarker discovery.Already a subscriber Login…
